{"id":"W4205173478","doi":"10.2217/fon-2021-1096","title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Cabozantinib; Medicine; Atezolizumab; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Clinical trial; Cancer; Nivolumab; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008006791,0.0002808939,0.001401433,0.0002470112,0.0001825272,0.00002384795,0.0002436563,0.00005761014,0.0007242298],"category_scores_gemma":[0.00002621105,0.0001874587,0.0000612052,0.0005388457,0.0001360969,0.0001424998,0.0001499414,0.0004662986,0.000001412548],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008830553,"about_ca_system_score_gemma":0.002188477,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00192255,"about_ca_topic_score_gemma":0.003625285,"domain_scores_codex":[0.9974299,0.0004697815,0.0006429495,0.0004769249,0.0005393412,0.0004410919],"domain_scores_gemma":[0.9986373,0.0002513141,0.0003933377,0.0003181993,0.0002657612,0.0001341104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9560444,0.02329654,0.001216055,0.00004389544,0.001532663,0.00036484,0.008037047,0.0000175712,0.00239451,0.00007664809,0.0005511086,0.006424685],"study_design_scores_gemma":[0.9324665,0.05118962,0.005866837,0.00002281761,0.0003046062,0.000007738914,0.005477837,0.00007845699,0.0001850705,0.000006039159,0.00420829,0.0001861532],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849012,0.002365011,0.000003173764,0.0006627126,0.0004016368,0.01024653,0.0005251385,0.00001572245,0.0008788646],"genre_scores_gemma":[0.9941168,0.0003187351,0.0002781414,0.0001337211,0.00006222759,0.003691825,0.0003519292,0.00004016822,0.001006412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02789309,"threshold_uncertainty_score":0.7929808,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05788647460081912,"score_gpt":0.3914232047436411,"score_spread":0.333536730142822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}